肝移植受者新发结直肠癌与胰腺癌:识别高危人群
该研究分析1997至2017年美国器官共享网络数据库中所有成人肝移植受者数据,并与普通人群癌症发病率比较。866例新发胃肠道恶性肿瘤中,结直肠癌405例、胰腺癌216例。原发性硬化性胆管炎(PSC)受者、50岁以上合并非酒精性脂肪性肝炎(NASH)和肝细胞癌(HCC)/胆管癌(CCA)的受者、以及50岁以上合并酒精性肝病和HCC/CCA的女性,结直肠癌累积发病率最高,且移植后5年内风险即高于普通人群。PSC合并HCC/CCA或NASH合并HCC/CCA的患者胰腺癌累积发病率最高,同样在移植后5年内升高,其中50岁以上患者风险最高。结论指出应针对这些高危人群考虑强化个体化结直肠癌筛查,并对胰腺癌高危人群进一步研究筛查策略。
要点
- PSC、50岁以上NASH合并HCC/CCA、50岁以上酒精性肝病合并HCC/CCA的女性结直肠癌风险最高。
- 上述人群结直肠癌风险在移植后5年内即高于普通人群。
- PSC合并HCC/CCA或NASH合并HCC/CCA者胰腺癌风险最高,移植后5年内升高。
核心结论
- 肝移植受者胃肠道恶性肿瘤发生率高于普通人群。
- 研究识别出结直肠癌和胰腺癌的高危肝移植受者队列,可考虑强化个体化筛查。
研究设计与样本
- 分析1997至2017年美国器官共享网络数据库中所有成人肝移植受者数据。
- 与监测、流行病学和最终结果(SEER)数据的普通人群癌症发病率进行比较。
主要发现
- 866例新发胃肠道恶性肿瘤中,结直肠癌405例,胰腺癌216例。
- 结直肠癌累积发病率最高见于PSC受者、50岁以上NASH合并HCC/CCA受者、50岁以上酒精性肝病合并HCC/CCA的女性。
- 上述人群结直肠癌风险在移植后5年内即高于普通人群。
- PSC合并HCC/CCA或NASH合并HCC/CCA的患者胰腺癌累积发病率最高,移植后5年内升高,50岁以上者风险最高。
临床怎么用
- 对PSC受者、50岁以上NASH合并HCC/CCA受者、50岁以上酒精性肝病合并HCC/CCA女性考虑强化个体化结直肠癌筛查。
- 对PSC合并HCC/CCA或NASH合并HCC/CCA的胰腺癌高危患者,需进一步研究以确定筛查策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Gastrointestinal (GI) malignancies are common after liver transplantation. The aim of this study was to identify the risk and timing of the more common GI malignancies, colorectal and pancreatic cancer, to aid in optimizing potential posttransplant screening practices. APPROACH AND RESULTS: Data from the United Network for Organ Sharing database of all adult liver-transplant recipients from 1997 to 2017 were analyzed and a comparison made with cancer incidence from general population data using Surveillance, Epidemiology, and End Results data. Of 866 de novo GI malignancies, 405 colorectal and 216 pancreas were identified. The highest cumulative incidence for colorectal cancer occurred in recipients with primary sclerosing cholangitis (PSC), recipients over the age of 50 with non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC)/cholangiocarcinoma (CCA), and females >50 years with alcohol-associated liver disease and HCC/CCA, with risk increasing above the general population within 5 years of transplant. Patients with PSC and HCC/CCA or NASH and HCC/CCA have the highest cumulative incidence of pancreatic cancer also rising within 5 years following transplant, with those patients >50 years old conferring the highest risk. CONCLUSIONS: These data identify a high-risk cohort that warrants consideration for intensified individualized screening practices for colorectal cancer after liver transplantation. In addition to recipients with PSC, further study of recipients with NASH and HCC/CCA and females with alcohol-associated liver disease and HCC/CCA may be better tailored to colorectal cancer screening ideals. Higher-risk patient populations for pancreatic cancer (PSC and NASH with HCC/CCA) would benefit from further study to determine potential screening practices. GI malignancies occur at higher rates in liver-transplant patients compared with the general population. In the era of individualized medicine, this study identifies the highest-risk transplant recipients (PSC and NASH cirrhosis with coexisting HCC/CCA) who may benefit from altered screening practices for these malignancies.
引用
- Nasser-Ghodsi N, Mara K, Watt KD, et al. De Novo Colorectal and Pancreatic Cancer in Liver-Transplant Recipients: Identifying the Higher-Risk Populations. Hepatology. 2021. PMID: 33544906. doi:10.1002/hep.31731
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。